90 related articles for article (PubMed ID: 4080643)
1. Chemoimmunotherapeutical studies on Dalton's lymphoma with cis-platin.
Bahadur A
Pol J Pharmacol Pharm; 1985; 37(4):463-8. PubMed ID: 4080643
[TBL] [Abstract][Full Text] [Related]
2. Induction of cell mediated immunity in vitro and in vivo after cis-platin treatment.
Bahadur A; Sodhi A
Pol J Pharmacol Pharm; 1985; 37(4):453-61. PubMed ID: 4080642
[TBL] [Abstract][Full Text] [Related]
3. Effect of allogenic Dalton's lymphoma cells on the activation of murine peritoneal macrophages to tumoricidal state by cisplatin and lipopolysaccharide (LPS).
Singh SM; Singh RK; Sodhi A
Neoplasma; 1992; 39(3):151-5. PubMed ID: 1528319
[TBL] [Abstract][Full Text] [Related]
4. Chemo-immunotherapeutical studies on Dalton's lymphoma in mice using cisplatin and ascorbic acid: synergistic antitumor effect in vivo and in vitro.
Sarna S; Bhola RK
Arch Immunol Ther Exp (Warsz); 1993; 41(5-6):327-33. PubMed ID: 8010874
[TBL] [Abstract][Full Text] [Related]
5. Enhanced cell mediated immunity in mice after cisplatin treatment.
Bahadur A; Sarna S; Sodhi A
Pol J Pharmacol Pharm; 1984; 36(5):441-8. PubMed ID: 6543466
[TBL] [Abstract][Full Text] [Related]
6. Use of subtherapeutical dose of cisplatin and vitamin C against murine Dalton's lymphoma.
Prasad SB; Giri A; Arjun J
Pol J Pharmacol Pharm; 1992; 44(4):383-91. PubMed ID: 1287602
[TBL] [Abstract][Full Text] [Related]
7. Structural and biochemical changes in mitochondria after cisplatin treatment of Dalton's lymphoma-bearing mice.
Prasad SB; Rosangkima G; Kharbangar A
Mitochondrion; 2010 Jan; 10(1):38-45. PubMed ID: 19766736
[TBL] [Abstract][Full Text] [Related]
8. Host CD4+ T lymphocytes are required for the synergistic action of interferon-alpha/beta and adoptively transferred immune cells in the inhibition of visceral ESb metastases.
Kaido TJ; Maury C; Gresser I
Cancer Res; 1995 Dec; 55(24):6133-9. PubMed ID: 8521404
[TBL] [Abstract][Full Text] [Related]
9. Effect of cis-dichlorodiammine platinum(II) on the agglutinability of tumor and normal cells with concanavalin A and wheat germ agglutinin.
Prasad SB; Sodhi A
Chem Biol Interact; 1981 Sep; 36(3):355-67. PubMed ID: 6895188
[TBL] [Abstract][Full Text] [Related]
10. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
11. A possible mechanism of tumor regression in cisplatin-treated mice.
Sarna S; Sodhi A; Bhola RK
Pol J Pharmacol Pharm; 1989; 41(1):69-76. PubMed ID: 2587438
[TBL] [Abstract][Full Text] [Related]
12. Host reactivity against clonable tumor cells and the total tumor cell population, studied in a syngeneic murine lymphoma system.
Gjedde SB
Acta Pathol Microbiol Immunol Scand C; 1983 Apr; 91(2):101-8. PubMed ID: 6349250
[TBL] [Abstract][Full Text] [Related]
13. Experimental studies on the treatment of hepatocellular carcinoma with cis-platin.transferrin complex.
Hamada Y
Hokkaido Igaku Zasshi; 1988 Nov; 63(6):864-74. PubMed ID: 2854816
[TBL] [Abstract][Full Text] [Related]
14. The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of rIL-2 administration.
Everse LA; Bernsen MR; Dullens HF; Den Otter W
J Exp Ther Oncol; 1996 Jul; 1(4):231-6. PubMed ID: 9414409
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect of cisplatin against murine ascites Dalton's lymphoma.
Prasad SB; Giri A
Indian J Exp Biol; 1994 Mar; 32(3):155-62. PubMed ID: 8070834
[TBL] [Abstract][Full Text] [Related]
16. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.
Sensi ML; Parenza M; Parmiani G
J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938
[TBL] [Abstract][Full Text] [Related]
17. Antitumour activity of some plants from Meghalaya and Mizoram against murine ascites Dalton's lymphoma.
Rosangkima G; Prasad SB
Indian J Exp Biol; 2004 Oct; 42(10):981-8. PubMed ID: 15511001
[TBL] [Abstract][Full Text] [Related]
18. Suppression of cell-mediated antitumor immunity by complete Freund's adjuvant.
Koyama S; Yoshioka T; Sakita T
Cancer Res; 1982 Aug; 42(8):3215-9. PubMed ID: 6980047
[TBL] [Abstract][Full Text] [Related]
19. Sex dimorphism in antitumor response of chemotherapeutic drug cisplatin in a murine host-bearing a T-cell lymphoma.
Gupta V; Singh SM
Anticancer Drugs; 2008 Jul; 19(6):583-92. PubMed ID: 18525317
[TBL] [Abstract][Full Text] [Related]
20. EblacZ tumor dormancy in bone marrow and lymph nodes: active control of proliferating tumor cells by CD8+ immune T cells.
Müller M; Gounari F; Prifti S; Hacker HJ; Schirrmacher V; Khazaie K
Cancer Res; 1998 Dec; 58(23):5439-46. PubMed ID: 9850077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
